{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:19Z","timestamp":1789676179831,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R310-2018-3711"],"award-info":[{"award-number":["R310-2018-3711"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.mayocp.2023.07.003","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T03:19:35Z","timestamp":1704424775000},"page":"285-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside"],"prefix":"10.1016","volume":"99","author":[{"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-9081","authenticated-orcid":false,"given":"Jan","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9558-5122","authenticated-orcid":false,"given":"Debbie L.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira","family":"Flores-Montanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien Phu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Icco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10283","key":"10.1016\/j.mayocp.2023.07.003_bib1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"10283","key":"10.1016\/j.mayocp.2023.07.003_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","article-title":"Migraine: integrated approaches to clinical management and emerging treatments","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"10.1016\/j.mayocp.2023.07.003_bib5","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2023.07.003_bib6","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults","volume":"325","author":"VanderPluym","year":"2021","journal-title":"JAMA"},{"issue":"10283","key":"10.1016\/j.mayocp.2023.07.003_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","article-title":"Migraine: disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2023.07.003_bib8","doi-asserted-by":"crossref","unstructured":"Goadsby P, Zanchin G, Geraud G, et\u00a0al. Early vs. non-early intervention in acute migraine\u2014 \u2018Act when Mild (AwM).\u2019 A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28(4):383-391. Published correction appears in Cephalalgia. 2008;28(6):679.","DOI":"10.1111\/j.1468-2982.2008.01546.x"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1468-2982.2005.01010.x","article-title":"Infrequent or non-response to oral sumatriptan does not predict response to other triptans\u2014review of four trials","volume":"26","author":"Dahl\u00f6f","year":"2006","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.mayocp.2023.07.003_bib10","first-page":"CD008541","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"Law","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2023.07.003_bib11","first-page":"CD008039","article-title":"Ibuprofen with or without an antiemetic for acute migraine headaches in adults","volume":"2013","author":"Rabbie","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2023.07.003_bib12","first-page":"CD008041","article-title":"Aspirin with or without an antiemetic for acute migraine headaches in adults","volume":"2013","author":"Kirthi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2023.07.003_bib13","first-page":"CD008783","article-title":"Diclofenac with or without an antiemetic for acute migraine headaches in adults","volume":"2013","author":"Derry","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/head.13663","article-title":"Efficacy, tolerability, and safety of DFN-15 (celecoxib oral solution, 25 mg\/mL) in the acute treatment of episodic migraine: a randomized, double-blind, placebo-controlled study","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.mayocp.2023.07.003_bib15","first-page":"2529","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled study of the efficacy, tolerability, and safety of celecoxib oral solution (ELYXYB) in acute treatment of episodic migraine with or without aura","volume":"14","author":"Lipton","year":"2021","journal-title":"J\u00a0Pain Res"},{"issue":"10","key":"10.1016\/j.mayocp.2023.07.003_bib16","first-page":"CD009455","article-title":"Naproxen with or without an antiemetic for acute migraine headaches in adults","volume":"2013","author":"Law","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.mayocp.2023.07.003_bib17","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"issue":"24","key":"10.1016\/j.mayocp.2023.07.003_bib18","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2023.07.003_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.mayocp.2023.07.003_bib20","doi-asserted-by":"crossref","unstructured":"Lipton RB, Dodick DW, Ailani J, et\u00a0al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. Published correction appears in JAMA. 2020;323(13):1318.","DOI":"10.1001\/jama.2019.16711"},{"issue":"23","key":"10.1016\/j.mayocp.2023.07.003_bib21","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10200","key":"10.1016\/j.mayocp.2023.07.003_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2023.07.003_bib26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0333102420938652","article-title":"Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache","volume":"40","author":"Navratilova","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J\u00a0Headache Pain"},{"issue":"11","key":"10.1016\/j.mayocp.2023.07.003_bib28","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/03007995.2020.1808780","article-title":"Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials","volume":"36","author":"Clemow","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.mayocp.2023.07.003_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","article-title":"The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines","volume":"52","author":"Loder","year":"2012","journal-title":"Headache"},{"key":"10.1016\/j.mayocp.2023.07.003_bib31","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345. Published correction appears in Neurology. 2013;80(9):871.","DOI":"10.1212\/WNL.0b013e3182535d20"},{"issue":"9","key":"10.1016\/j.mayocp.2023.07.003_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"issue":"10268","key":"10.1016\/j.mayocp.2023.07.003_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2023.07.003_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0333102420981666","article-title":"Hypersensitivity to calcitonin gene\u2013related peptide in chronic migraine","volume":"41","author":"Iljazi","year":"2021","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.mayocp.2023.07.003_bib37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.bjp.0703110","article-title":"Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist","volume":"129","author":"Doods","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.mayocp.2023.07.003_bib38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene\u2013related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10161","key":"10.1016\/j.mayocp.2023.07.003_bib39","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2023.07.003_bib40","doi-asserted-by":"crossref","unstructured":"Ferrari MD, Diener HC, Ning X, et\u00a0al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030-1040. Published correction appears in Lancet. 2019 Oct 29:S0140-6736(19)32643-1.","DOI":"10.1016\/S0140-6736(19)31946-4"},{"issue":"10","key":"10.1016\/j.mayocp.2023.07.003_bib41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive\u00a0medication from two to four categories had failed (CONQUER):\u00a0a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2023.07.003_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231170807","article-title":"Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study","volume":"43","author":"Ashina","year":"2023","journal-title":"Cephalalgia"},{"issue":"4-5","key":"10.1016\/j.mayocp.2023.07.003_bib43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study","volume":"42","author":"Raffaelli","year":"2022","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.mayocp.2023.07.003_bib45","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10210","key":"10.1016\/j.mayocp.2023.07.003_bib46","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene\u2013related peptide: a new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/head.13588","article-title":"Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment study","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.mayocp.2023.07.003_bib49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"issue":"3","key":"10.1016\/j.mayocp.2023.07.003_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0333102418765787","article-title":"Molecular studies of CGRP and the CGRP family of peptides in the central nervous system","volume":"39","author":"Hendrikse","year":"2019","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.mayocp.2023.07.003_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-7634(96)00023-1","article-title":"Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors","volume":"21","author":"Van Rossum","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.mayocp.2023.07.003_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170347","article-title":"Adrenomedullin\u2014current perspective on a peptide hormone with significant therapeutic potential","volume":"131","author":"Fischer","year":"2020","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mayocp.2023.07.003_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.peptides.2014.01.009","article-title":"Involvement of adrenomedullin in the attenuation of acute morphine-induced analgesia in rats","volume":"54","author":"Wang","year":"2014","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.mayocp.2023.07.003_bib55","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ejp.898","article-title":"Amylin modulates the formalin-induced tonic pain behaviours in rats","volume":"20","author":"Potes","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.mayocp.2023.07.003_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.npep.2015.12.011","article-title":"Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in\u00a0the rat embryonic spinal cells","volume":"57","author":"Khoshdel","year":"2016","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0169-328X(98)00269-1","article-title":"Reduced nociceptive behavior in islet amyloid polypeptide\u00a0(amylin) knockout mice","volume":"63","author":"Gebre-Medhin","year":"1998","journal-title":"Mol Brain Res"},{"issue":"43","key":"10.1016\/j.mayocp.2023.07.003_bib58","doi-asserted-by":"crossref","first-page":"16027","DOI":"10.1073\/pnas.0602488103","article-title":"A\u00a0role for adrenomedullin as a pain-related peptide in the rat","volume":"103","author":"Ma","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.mayocp.2023.07.003_bib59","doi-asserted-by":"crossref","first-page":"e2488","DOI":"10.1212\/WNL.0000000000011930","article-title":"Effect of adrenomedullin on migraine-like attacks in patients with migraine","volume":"96","author":"Ghanizada","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2023.07.003_bib60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0031-6997(24)01449-2","article-title":"Pituitary adenylate cyclase\u2013activating polypeptide and its receptors: from structure to functions","volume":"52","author":"Vaudry","year":"2000","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"issue":"pt 1","key":"10.1016\/j.mayocp.2023.07.003_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","journal-title":"Brain"},{"issue":"pt 3","key":"10.1016\/j.mayocp.2023.07.003_bib64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/awt369","article-title":"Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase\u2013activating polypeptide-38","volume":"137","author":"Amin","year":"2014","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18543","article-title":"Effect of vasoactive intestinal polypeptide on development of migraine headaches","volume":"4","author":"Pellesi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A\u00a0phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase\u2013-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.mayocp.2023.07.003_bib67","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/j.pain.0000000000001858","article-title":"PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?","volume":"161","author":"Hoffmann","year":"2020","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.mayocp.2023.07.003_bib68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1468-2982.2008.01807.x","article-title":"The in\u00a0vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery","volume":"29","author":"Boni","year":"2009","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.mayocp.2023.07.003_bib69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejphar.2011.08.016","article-title":"Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat","volume":"670","author":"Baun","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.07.003_bib70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.npep.2012.12.005","article-title":"VIP\/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium","volume":"47","author":"Erdling","year":"2013","journal-title":"Neuropeptides"},{"issue":"308","key":"10.1016\/j.mayocp.2023.07.003_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7557","article-title":"Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine","volume":"7","author":"Akerman","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.mayocp.2023.07.003_bib72","doi-asserted-by":"crossref","unstructured":"Rasmussen NB, Deligianni C, Christensen CE, et\u00a0al. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain. 2023;24(1):60. Published correction appears in J Headache Pain. 2023;24(1):74.","DOI":"10.1186\/s10194-023-01610-4"},{"issue":"9","key":"10.1016\/j.mayocp.2023.07.003_bib25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","article-title":"Pathophysiology, prevention, and treatment of medication overuse headache","volume":"18","author":"Diener","year":"2019","journal-title":"Lancet Neurol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:41:06Z","timestamp":1758418866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619623003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0025619623003324"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.07.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}